{"id":"W4282967222","doi":"10.1158/1538-7445.am2022-ct007","title":"Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Prostate cancer; Olaparib; Oncology; Pharmacodynamics; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Progressive disease; PARP inhibitor; Cancer; Gastroenterology; Clinical trial; Phases of clinical research; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005552629,0.001011096,0.001070271,0.0003123712,0.0004751588,0.0009071594,0.0007097597,0.0009631935,0.01514584],"category_scores_gemma":[0.0005504828,0.0003972964,0.0007188463,0.0002944006,0.0006546969,0.0004712272,0.0003843507,0.002704066,0.002236113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001017596,"about_ca_system_score_gemma":0.001753815,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001264391,"about_ca_topic_score_gemma":0.003410678,"domain_scores_codex":[0.9997991,0.00008130253,0.000008108575,0.00003541066,0.00002284307,0.0000531869],"domain_scores_gemma":[0.9996321,0.00004568102,0.00005479297,0.00002492865,0.00001588272,0.0002265403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7288113,0.02824686,0.008404276,0.001209228,0.001231125,0.0007154242,0.0002681501,0.003546839,0.04008132,0.001201412,0.03375892,0.1525252],"study_design_scores_gemma":[0.607413,0.3426284,0.01517575,0.0001361866,0.0005180158,0.001443935,0.00005838948,0.002262527,0.00723418,0.000694792,0.02238888,0.0000459358],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9681957,0.004216772,0.001268034,0.001735937,0.0002294401,0.003726214,0.005488189,0.0005466549,0.01459312],"genre_scores_gemma":[0.9720988,0.002283125,0.001786204,0.001279382,0.0002457167,0.0019286,0.006436627,0.00008537182,0.01385619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01514584,"threshold_uncertainty_score":0.05066788,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1556164151283519,"score_gpt":0.4129968895698667,"score_spread":0.2573804744415147,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}